Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, January 16, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Incyte Corporation (NASDAQ: INCY), and Varian Medical Systems Inc. (NYSE: VAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On January 13, 2014, Gilead Sciences Inc. (Gilead) announced that the US Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for idelalisib, a targeted, oral inhibitor of PI3K delta, for the treatment of refractory indolent non-Hodgkin's lymphoma (iNHL). According to the Company, FDA has granted a standard review for the iNHL NDA and has set a target review date of September 11, 2014 under the Prescription Drug User Fee Act (PDUFA). The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  

http://www.analystscorner.com/r/full_research_report/9898_GILD

Eli Lilly & Co. Research Report

On January 13, 2014, Eli Lilly & Co. (Lilly) announced that it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody, currently being studied as a potential treatment for the prevention of frequent or recurrent migraine headaches from Arteaus Therapeutics. According to the Company, CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two processes that have been implicated in migraine headaches. According to Lilly, its CGRP antibody is a biologic entity injected subcutaneously that binds and inhibits the activity of CGRP, which is released during activation of sensory neurons involved in pain signaling. David Grayzel, MD, CEO of Arteaus Therapeutics, said, "We view Lilly's acquisition of the CGRP antibody program as further validation for this innovative biotech model of collaborative drug development." According to the Lilly, as a result of its decision to acquire the CGRP antibody, the Company is expected to incur a Q4 2013 pre-tax charge of c.$57.1 million, or c.$0.03 per share after-tax charge. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

Allergan Inc. Research Report

On January 9, 2014, Allergan Inc. (Allergan) announced that the Chairman of its Board and CEO, David Pyott, and Executive Vice President, Finance and Business Development, CFO, Jeff Edwards, will discuss the Company's Q4 2013 and full-year 2013 results on February 5, 2014. The Company informed that a live webcast of the discussion can be accessed by interested parties via the Allergan website, starting at 8:00 a.m. PT. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/182a_AGN

Incyte Corporation Research Report

On January 13, 2014, Incyte Corporation (Incyte) announced that former President of Novartis Oncology, Herve Hoppenot has been appointed as President and CEO of the Company with immediate effect. According to the Company, Hoppenot will also join Incyte's Board of Directors, succeeding Paul A. Friedman, M.D. "Hervé's broad international oncology experience and proven track record in leading successful, high-performing R&D and commercial teams will be of great value as we continue to build upon Incyte's remarkable success," said Richard De Schutter, Chairman of Incyte's Board of Directors. "At the time we welcome Hervé to the Incyte team, we especially want to thank and recognize Dr. Friedman for his extraordinary leadership of the company during his tenure as CEO. It is his leadership, together with the quality of the team he assembled, that has enabled Incyte to become the successful biopharmaceutical company it is today." The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/076e_INCY

Varian Medical Systems Inc. Research Report

On January 6, 2014, Varian Medical Systems Inc. (Varian Medical Systems) announced the publication of its 2013 Annual Report. According to the Company, a PDF version of the Varian 2013 annual report can be accessed by interested parties via a link provided in Varian Medical Systems' website. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bd48_VAR

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.